336 related articles for article (PubMed ID: 26671081)
1. Spontaneous downbeat nystagmus as a clue for the diagnosis of ataxia associated with anti-GAD antibodies.
Vale TC; Pedroso JL; Alquéres RA; Dutra LA; Barsottini OG
J Neurol Sci; 2015 Dec; 359(1-2):21-3. PubMed ID: 26671081
[TBL] [Abstract][Full Text] [Related]
2. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association.
Saiz A; Blanco Y; Sabater L; González F; Bataller L; Casamitjana R; Ramió-Torrentà L; Graus F
Brain; 2008 Oct; 131(Pt 10):2553-63. PubMed ID: 18687732
[TBL] [Abstract][Full Text] [Related]
3. Auto-immune cerebellar ataxia with anti-GAD antibodies accompanied by de novo late-onset type 1 diabetes mellitus.
Bayreuther C; Hieronimus S; Ferrari P; Thomas P; Lebrun C
Diabetes Metab; 2008 Sep; 34(4 Pt 1):386-8. PubMed ID: 18583169
[TBL] [Abstract][Full Text] [Related]
4. Potential role of anti-GAD antibodies in abnormal eye movements.
Tilikete C; Vighetto A; Trouillas P; Honnorat J
Ann N Y Acad Sci; 2005 Apr; 1039():446-54. PubMed ID: 15826997
[TBL] [Abstract][Full Text] [Related]
5. [Clinical characteristics of four patients with temporal lobe epilepsy associated with elevated anti-GAD antibodies].
Akaishi T; Jin K; Kato K; Itabashi H; Misu T; Tateyama M; Iwasaki M; Aoki M; Nakasato N
Rinsho Shinkeigaku; 2015; 55(11):804-9. PubMed ID: 26369378
[TBL] [Abstract][Full Text] [Related]
6. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients.
Honnorat J; Saiz A; Giometto B; Vincent A; Brieva L; de Andres C; Maestre J; Fabien N; Vighetto A; Casamitjana R; Thivolet C; Tavolato B; Antoine J; Trouillas P; Graus F
Arch Neurol; 2001 Feb; 58(2):225-30. PubMed ID: 11176960
[TBL] [Abstract][Full Text] [Related]
7. Anti-GAD antibodies and periodic alternating nystagmus.
Tilikete C; Vighetto A; Trouillas P; Honnorat J
Arch Neurol; 2005 Aug; 62(8):1300-3. PubMed ID: 16087772
[TBL] [Abstract][Full Text] [Related]
8. [A new case of cerebellar ataxia with anti-GAD antibodies treated with corticosteroids and initially seronegative].
Birand B; Cabre P; Bonnan M; Olindo S; Smadja D
Rev Med Interne; 2006 Aug; 27(8):616-9. PubMed ID: 16797794
[TBL] [Abstract][Full Text] [Related]
9. [Steroid treatment in four cases of anti-GAD cerebellar ataxia].
Bonnan M; Cabre P; Olindo S; Signate A; Saint-Vil M; Smadja D
Rev Neurol (Paris); 2008 May; 164(5):427-33. PubMed ID: 18555874
[TBL] [Abstract][Full Text] [Related]
10. Acute Cerebellar Ataxia Associated with Anti-glutamic Acid Decarboxylase Antibodies Mimicking Miller Fisher Syndrome.
Nakamura Y; Nakajima H; Hosokawa T; Yamane K; Ishida S; Kimura F
Intern Med; 2018 Jan; 57(2):269-271. PubMed ID: 29093402
[TBL] [Abstract][Full Text] [Related]
11. Cerebellar ataxia and epilepsy with anti-GAD antibodies: treatment with IVIG and plasmapheresis.
Georgieva Z; Parton M
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24419643
[TBL] [Abstract][Full Text] [Related]
12. Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies.
Vulliemoz S; Vanini G; Truffert A; Chizzolini C; Seeck M
J Neurol Neurosurg Psychiatry; 2007 Feb; 78(2):187-9. PubMed ID: 17229747
[TBL] [Abstract][Full Text] [Related]
13. Vertical nystagmus associated with glutamic acid decarboxylase antibodies responding to cyclophosphamide.
Baizabal-Carvallo JF; Alonso-Juarez M
J Neuroimmunol; 2018 Apr; 317():5-7. PubMed ID: 29501085
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis.
Malter MP; Helmstaedter C; Urbach H; Vincent A; Bien CG
Ann Neurol; 2010 Apr; 67(4):470-8. PubMed ID: 20437582
[TBL] [Abstract][Full Text] [Related]
15. Opsoclonus in a patient with increased titers of anti-GAD antibody provides proof for the conductance-based model of saccadic oscillations.
Shaikh AG; Wilmot G
J Neurol Sci; 2016 Mar; 362():169-73. PubMed ID: 26944142
[TBL] [Abstract][Full Text] [Related]
16. Glutamic acid decarboxylase antibody-associated neurological syndromes: Clinical and antibody characteristics and therapy response.
Madlener M; Strippel C; Thaler FS; Doppler K; Wandinger KP; Lewerenz J; Ringelstein M; Roessling R; Menge T; Wickel J; Kellingshaus C; Mues S; Kraft A; Linsa A; Tauber SC; Berg FT; Gerner ST; Paliantonis A; Finke A; Priller J; Schirotzek I; Süße M; Sühs KW; Urbanek C; Senel M; Sommer C; Kuempfel T; Pruess H; Fink GR; Leypoldt F; Melzer N; Malter MP;
J Neurol Sci; 2023 Feb; 445():120540. PubMed ID: 36608627
[TBL] [Abstract][Full Text] [Related]
17. Low-Titre GAD Antibody-Associated Late-Onset Cerebellar Ataxia with a Significant Clinical Response to Intravenous Immunoglobulin Treatment.
Petrijan T; Menih M
Cerebellum; 2017 Aug; 16(4):868-871. PubMed ID: 28321713
[TBL] [Abstract][Full Text] [Related]
18. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases.
Manto MU; Laute MA; Aguera M; Rogemond V; Pandolfo M; Honnorat J
Ann Neurol; 2007 Jun; 61(6):544-51. PubMed ID: 17600364
[TBL] [Abstract][Full Text] [Related]
19. Gravity-Independent Upbeat Nystagmus in Syndrome of Anti-GAD Antibodies.
Feldman D; Otero-Millan J; Shaikh AG
Cerebellum; 2019 Apr; 18(2):287-290. PubMed ID: 30136028
[TBL] [Abstract][Full Text] [Related]
20. Autoantibodies to glutamic acid decarboxylase in downbeat nystagmus.
Antonini G; Nemni R; Giubilei F; Gragnani F; Ceschin V; Morino S; Bucci E; Accornero N
J Neurol Neurosurg Psychiatry; 2003 Jul; 74(7):998-9. PubMed ID: 12810806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
